



## Early View

Research letter

### **Incidence and Significance of Venous Thromboembolism in Critically ill Pulmonary Tuberculosis Patients**

Angela Lau, Wendy Sligl, Ken Sun, James Barrie, Richard Long

Please cite this article as: Lau A, Sligl W, Sun K, *et al.* Incidence and Significance of Venous Thromboembolism in Critically ill Pulmonary Tuberculosis Patients. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.01753-2020>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

## **RESEARCH LETTER**

### **INCIDENCE AND SIGNIFICANCE OF VENOUS THROMBOEMBOLISM IN CRITICALLY ILL PULMONARY TUBERCULOSIS PATIENTS**

**Running Title:** Venous Thromboembolism in Critically Ill Pulmonary TB Patients

**Word Count:** Text 1248; 1 Figure

**Angela Lau,<sup>1</sup> Wendy Sligl,<sup>2</sup> Ken Sun,<sup>1</sup> James Barrie,<sup>3</sup> and Richard Long<sup>1</sup>**

From the Department of Medicine,<sup>1</sup> Department of Critical Care Medicine,<sup>2</sup> and the Department of Radiology and Diagnostic Imaging,<sup>3</sup> Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

Address for correspondence:

Richard Long, MD  
Room 8334A, 3rd Floor, Aberhart Centre  
11402 University Avenue NW  
Edmonton, Alberta  
Canada, T6G 2J3

Phone: (780) 407-1427

Fax: (780) 407-1429

Email: richard.long@ualberta.ca

*To the Editor:*

Venous thromboembolism (VTE) has not been reported to be a contributor to the poor outcomes in pulmonary tuberculosis (PTB) patients requiring intensive care [1]. Hemostatic changes that favour the development of VTE, however, are well documented in PTB [2-4] and, compared to patients without active TB, those with active TB are known to be at increased risk for VTE [5]. We have been impressed by the frequency with which clinically diagnosed VTE, both deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE), are present in critically ill PTB patients (where “PTB” refers to both adult-type pulmonary TB and miliary/disseminated TB), with critical illness being either the cause or effect of VTE. Herein we document this high frequency and raise awareness of this potentially serious complication.

We conducted a retrospective observational cohort study of all adult (age > 17 years) smear-positive, culture-positive PTB patients admitted over an eleven year period beginning January 1, 2006, to the University of Alberta Hospital, the TB referral hospital for the city of Edmonton and all of rural Alberta, Canada. In Alberta, smear-positive PTB patients are routinely admitted to hospital; those not diagnosed with VTE on admission are prescribed DVT prophylaxis (standard dose low molecular weight heparin). We used administrative and radiology databases to determine which PTB patients required intensive care (ICU) and which were investigated for DVT or PTE. DVT were diagnosed by compression ultrasonography; PTE by helical computerized tomographic pulmonary angiography (CTPA).

Demographic and clinical characteristics of PTB patients who did or did not require ICU and admission PF ratios ( $\text{PaO}_2/\text{FiO}_2$ ) in ICU-requiring PTB cases who did or did not have VTE, were compared. The timing of VTE investigations relative to the date of diagnosis of PTB (the start date of anti-tuberculosis drug treatment) and the outcomes of those investigations were recorded. Each VTE event was described; for patients with PTE this included having each CTPA re-read by an experienced, university-based chest radiologist who confirmed the event and documented the anatomical location of PTE relative to the

anatomical location of PTB. VTE diagnosed at the time of or up to 30 days before the diagnosis of PTB were considered prevalent events; VTE diagnosed after the diagnosis of PTB but before discharge from hospital were considered incident events. TB-related death—occurring during treatment of active disease, where TB was considered the primary or contributory cause of death—was compared in VTE-tested PTB patients with and without VTE. Univariate analysis was performed for categorical data using Pearson's chi-squared test or Fisher's exact test as appropriate. A two-tailed p-value  $<0.05$  was taken as statistically significant. Appropriate institutional ethics approval was obtained.

Over the study years, 240 PTB patients were admitted to hospital; of these, 20 (8.3%) required intensive care and 10 (4.2%) were diagnosed with VTE (see Figure 1). Nineteen of the 20 ICU admissions were for respiratory insufficiency; one was for hypotension requiring vasopressor support. Patients requiring intensive care were older ( $> 64$  years), 45.0% vs 19.1%,  $p=0.01$ , and more likely to have miliary/disseminated TB, 50% vs 13.6%,  $p=0.0002$ , to have longer hospital lengths of stay, median days (interquartile range) 39.5 (17.3-74.3) vs 23.0 (14.0-38.8),  $p=0.03$ , and to die in hospital, 20.0% vs 1.8%,  $p=0.0005$ . They did not differ by sex, population group, HIV status, or drug resistance pattern (data not shown). ICU patients with VTE were more likely than those without to have a severe PF ratio ( $<100$ ) on admission, 50.0% vs 0.0%,  $p=0.03$  (data not shown). In four patients the diagnosis of VTE was made at the time of or up to 30 days before the diagnosis of PTB; in two of these four, one with DVT and PTE and another with PTE alone, the VTE and PTB diagnoses and ICU admission followed in rapid succession, with VTE judged to be a major contributor to the need for intensive care (patients #1 and #3 in Figure 1).

In six patients the diagnosis of VTE was made after the diagnosis of PTB and while the patient was either in the ICU or after discharge from the ICU but before discharge from hospital. These patients had all been placed on DVT prophylaxis for a median of 27 days, range 8 to 81 days (see time from diagnosis of PTB to VTE in Figure 1). No incident VTE occurred in hospitalized PTB patients that did not require intensive

care. Among the six patients experiencing a PTE, the clot had gone to relatively non-TB-diseased lung in four, to both TB-diseased and non-TB-diseased lung in one, and to TB-diseased lung alone in one. In this last patient (#5 in Figure 1) clot was favoured to represent in-situ thrombosis over PTE. The prevalence of VTE was 1.7% (95% confidence interval [CI], 0.6%-4.2%); the incidence of VTE in hospitalized PTB patients who required intensive care was 33.3% (95% CI, 16.3%-56.3%)—27.8% if the patient favoured to have in-situ thrombosis, and not PTE, was discounted.

Amongst VTE-tested PTB patients (n=47), a TB-related death was reported in 6/10 (60.0%) of those with and 4/37 (10.8%) of those without VTE (OR 12.4 [95% CI, 2.4-63.6], p=0.003) (data not shown).

The remarkably high incidence of clinically diagnosed VTE reported herein is much higher than the 1-2% incidence reported in critically ill medical-surgical patients in general [6]. And, while DVT prophylaxis prevented VTE in the 218 patients who were not admitted to ICU (and not already diagnosed with VTE), it did not prevent VTE in 6 of the 18 patients who were admitted to ICU (and not already diagnosed with VTE). Thus, the hypercoagulable state of PTB appeared to be manageable with routine DVT prophylaxis in all but those requiring ICU. PTB patients requiring ICU were similar to those reported elsewhere in Canada [7]. Presumably their critical-illness-related risk of VTE – attributed to immobility, neuromuscular blockade, vasopressors, sepsis and central nervous catheterization – and/or critical-illness-related failure to absorb DVT prophylaxis – attributed to decreased subcutaneous perfusion secondary to edema/vasopressors – rendered routine DVT prophylaxis inadequate [8,9]. In unadjusted analysis VTE carried a significant mortality risk.

Independent of ICU, PTB patients with PTE are known to have a higher pulmonary embolism severity index (PESI) and more frequently have a high PESI class than control non-PTB patients with unprovoked PTE [10]. In this regard it is noteworthy that the pathophysiologic defect in uncomplicated PTB is one in which ventilation and perfusion to diseased lung is reduced in parallel and gas exchange is relatively well

preserved [11]. This would predict that PTE, if they occur, are more likely to migrate to relatively normal lung and have a greater deleterious effect on gas exchange (increase in physiologic dead space), the smaller the volume of normal lung remaining. With the exception of one patient, who was favoured to have in-situ thrombosis, PTE had migrated to relatively non-TB-diseased lung; upon admission to ICU patients with VTE were more likely than those without, to have severe PaO<sub>2</sub>/FiO<sub>2</sub> ratios. The occurrence of PTE, if associated with an elevated pulmonary artery pressure, would also predict that Rasmussen aneurysms, if present, would be more likely to rupture, further compromising gas exchange. They are present in 4% of chronic cavitary PTB patients [12].

The incidence, morbidity and mortality data presented here strongly suggest the need for a high index of suspicion for VTE in PTB patients requiring intensive care. Until alternative preventive measures such as high dose prophylaxis are proven to be effective [13], and given that lower limb DVT are the primary source of PTE [14], the systematic screening of ICU-requiring PTB patients for DVT may be warranted [15].

## REFERENCES

1. Hagan G, Nathani N. Clinical review: tuberculosis on the intensive care unit. *Crit Care*. 2013;17(5):240. doi:10.1186/cc12760.
2. Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. *Br J Haematol*. 1996;93(4):943-9.
3. Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E, Ozturk A, Ilvan A. Hemostatic changes in active pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2002;6(10):927-32.
4. Kager LM, Blok DC, Lede IO, Rahman W, Afroz R, Bresser P, van der Zee JS, Ghose A, Visser CE, de Jong MD, Tanck MW, Zahed AS, Alam KM, Hassan M, Hossain A, Lutter R, Veer CV, Dondorp AM, Meijers JC, van der Poll T. Pulmonary tuberculosis induces a systemic hypercoagulable state. *J Infect*. 2015;70(4):324-34. doi:10.1016/j.jinf.2014.10.006.
5. Dentan C, Epaulard O, Seynaeve D, Genty C, Bosson JL. Active tuberculosis and venous thromboembolism: association according to international classification of diseases, ninth revision hospital discharge diagnosis codes. *Clin Infect Dis*. 2014;58:495-501.
6. Patel R, Cook DJ, Meade MO, Griffith LE, Mehta G, Rocker GM, Marshall JC, Hodder R, Martin CM, Heyland DK, Peters S, Muscedere J, Soth M, Campbell N, Guyatt GH; Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators; Canadian Critical Care Trials Group. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. *J Crit Care*. 2005;20(4):341-7. doi:10.1016/j.jcrc.2005.09.014.
7. Penner C, Roberts D, Kunimoto D, Manfreda J, Long R. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. *Am J Respir Crit Care Med*. 1995;151:867-72.
8. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, Cartier JC, Ferretti G, Schwebel C, Timsit JF. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. *Crit Care*. 2015;19(1):287.
9. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:381S-453S. doi:10.1378/chest.08-0656.
10. Park H, Cha S-I, Lim JK, Nyeo Jeon K, Yoo S-S, Lee J, Lee S-Y, Kim C-H, Park J-Y. Clinical characteristics of coexisting pulmonary thromboembolism in patients with respiratory tuberculosis. *Am J Med Sci*. 2017;353(2):166-71. doi:10.1016/j.amjms.2016.11.025.
11. Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. *Chest*. 1998 113(4):933-43.
12. Auerbach, O. Pathology and pathogenesis of pulmonary arterial aneurysms in tuberculous cavities. *Am Rev Tuberc*. 1939; 39:99-115.
13. Shaikh S, Boneva D, Hai S, McKenney M, Elkbuli A. Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: A systematic review. *J Trauma Acute Care Surg*. 2020;88(4):522-35. doi:10.1097/TA.0000000000002538.
14. Saeger W, Genzkow M. Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlations of clinical data and basic diseases. *Pathol Res Pract*. 1994;190(4):394-9.
15. Kory PD, Pellecchia CM, Shiloh AL, Mayo PH, DiBello C, Koenig S. Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT. *Chest* 2011;139(3):538-42. doi:10.1378/chest.10-1479.

**FIGURE 1. Hospitalized PTB Patients: Individual ICU and VTE Histories**

